ReviewMicrobial pathogenesis2020
Immune response in COVID-19: What do we currently know?
Review in Microbial pathogenesis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Characteristics of COVID-19 Recurrence: A Systematic Review and Meta-Analysis.Annals of global health · 2021Pooled it
- Aryl hydrocarbon receptor activation alters immune cell populations in the lung and bone marrow during coronavirus infection.American journal of physiology. Lung cellular and molecular physiology · 2024Article
- Association of triglyceride/high-density lipoprotein cholesterol ratio with severe complications of COVID-19.Heliyon · 2023Article
- Temporal patterns of cytokine and injury biomarkers in hospitalized COVID-19 patients treated with methylprednisolone.Frontiers in immunology · 2023Article
- Evaluation of the Levels of Peripheral CD3Microbiology spectrum · 2022Article
- Metabolomics Signatures of SARS-CoV-2 Infection.Advances in experimental medicine and biology · 2022Review
- Citicoline and COVID-19-Related Cognitive and Other Neurologic Complications.Brain sciences · 2021Review
- Critical Update on the Diagnosis and Management of COVID-19 in Advanced Cirrhosis and Liver Transplant Recipients.Journal of clinical and translational hepatology · 2021Review
- High triglyceride to HDL-cholesterol ratio as a biochemical marker of severe outcomes in COVID-19 patients.Clinical nutrition ESPEN · 2021Observational
- Abscopal antitumor effect in a patient with melanoma and coronavirus disease 2019.European journal of cancer (Oxford, England : 1990) · 2021Article
- AYUSH- 64: A potential therapeutic agent in COVID-19.Journal of Ayurveda and integrative medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2002/2003 there was a pandemic denominate SARS (severe acute respiratory syndrome), caused by the SARS-CoV virus that belongs to the genera Betacoranavirus and the family Coronaviridae, generally responsible for influenza infections. In mid of 2019, a new disease by the coronavirus named by COVID-19 (SARS-CoV-2) emerged, both infections have flu symptoms, however they are infections that variable intensity, being medium to severe. In medium infections individuals have the virus and exhibit symptoms, however hospitalization is not necessary, in severe infections, individuals are hospitalized, have high pathology and in some cases progress to death. The virus is formed by simple positive RNA, enveloped, non-segmented, and presenting the largest genome of viruses constituting 32 Kb, consisting of envelope proteins, membrane, nucleocapsid and spike protein, which is essential in the interaction with the host cells. As for the origin of this virus, research has been intensified to determine this paradox and although the similarity with SARS-CoV, this virus did not has necessarily the same place of origin. As for the immune system, it is currently unknown how this new virus interacts. In this brief review, we demonstrate important considerations about the responses to this infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.